TICKERNERD
Menu
JNJJNJHealthcare · Drug Manufacturers - General

JNJ Stock Forecast: Johnson & Johnson Price Predictions for 2026-2027

Last close, 3 Aug 2026
$254
−0.76% on the day

The 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $274 — +7.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 1 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$617.8B
Ticker Nerd rank
94 / 100
Median analyst target
$274
Analysts covering
23
Total return, dividends reinvested
1W
−4.3%
1M
−3.3%
YTD
+24.3%
1Y
+55.8%
From 52W high
−4.8%
From 52W low
+52.8%
$166
$267
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

JNJ stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Quality
94
Value
88
Issuance
88
Momentum
86
Revisions
79
Growth
63
Accruals
47
Size
0

Volatility (100): The share price has been relatively steady.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership.

Wall Street

JNJ stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250$300Oct 25Jan 26Apr 26Jul 26JNJHigh $305Median $274Low $190

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says23 analysts
16 Buy6 Hold1 Sell
Low $190Median $274High $305

The green dot is the last close — the median target sits +7.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
3 Aug 2026Wells FargoMaintainsOverweight$272 → $282
17 July 2026GuggenheimReiteratesBuy$270
16 July 2026Morgan StanleyMaintainsOverweight$284 → $294
16 July 2026Raymond JamesMaintainsOutperform$258 → $265
16 July 2026RBC CapitalReiteratesOutperform$287
16 July 2026Wells FargoMaintainsOverweight$263 → $272
13 July 2026RBC CapitalMaintainsOutperform$265 → $287
13 July 2026TD CowenMaintainsBuy$250 → $300
10 July 2026B of A SecuritiesMaintainsNeutral$254 → $263
8 July 2026CitigroupMaintainsBuy$285 → $298
8 July 2026CitigroupMaintainsBuy—
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$283 → $284
26 June 2026GuggenheimMaintainsBuy—
13 May 2026Leerink PartnersUpgradeOutperform—
15 Apr 2026BarclaysMaintainsEqual-Weight—
15 Apr 2026StifelMaintainsHold—
15 Apr 2026Wells FargoMaintainsOverweight—
10 Apr 2026Morgan StanleyMaintainsOverweight—
8 Apr 2026TD CowenAssumesBuy$250

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

JNJ analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+0.9%
Analysts raising
2
Analysts cutting
0
Fundamentals

Johnson & Johnson (JNJ) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
29.8×

Cheaper than 28% of US stocks

Price / sales
6.3×

Cheaper than 20% of US stocks

Price / book
7.3×

Cheaper than 14% of US stocks

EV / EBITDA
18.5×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
6.6%

Higher than 46% of US stocks

Earnings growth (YoY)
−0.1%

Higher than 36% of US stocks

Gross margin
68.2%

Higher than 82% of US stocks

Operating margin
29.2%

Higher than 87% of US stocks

Net margin
21.5%

Higher than 83% of US stocks

Returns & dividend
Return on equity
25.7%

Higher than 86% of US stocks

Return on assets
8.6%

Higher than 90% of US stocks

Dividend yield
2.1%

Higher than 47% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

JNJ vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
JNJJohnson & Johnson$617.8B
94
ABBVAbbVie, Inc.$443.4B
91
LLYEli Lilly & Co.$1.1T
77
MRKMerck & Co., Inc.$323.2B
69
AMGNAmgen, Inc.$207.6B
86
GILDGilead Sciences, Inc.$161.6B
89
PFEPfizer Inc.$142.2B
69
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. JNJ appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest JNJ news & analysis

Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript

Seeking Alpha · 3 Aug 2026neutral

The item is a transcript of Johnson & Johnson discussing the FDA authorization and market introduction of its OTTAVA robotic surgical system, as published on Seeking Alpha. It covers the company's remarks on the system's regulatory status and launch plans.

Why it matters — A JNJ watcher would care because the OTTAVA robotic surgical system is part of the company's medtech portfolio, and its FDA authorization and market introduction could affect that segment.

J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes

Zacks Investment Research · 3 Aug 2026positive

Johnson & Johnson reported strong second-quarter growth in its oncology business, with Darzalex, Erleada and newer cancer drugs boosting sales and advancing the company's long-term ambitions.

Why it matters — A J&J watcher would care because oncology is a key growth driver for the company's pharmaceutical segment.

Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?

Zacks Investment Research · 3 Aug 2026neutral

The article discusses how Wall Street analysts' recommendations are often used by investors to guide buy, sell, or hold decisions on stocks like Johnson & Johnson, and notes that media reports of analyst rating changes can influence stock prices.

Why it matters — JNJ watchers would care because shifts in analyst ratings can affect the stock's short-term price movement and reflect professional sentiment about the company's outlook.

Johnson & Johnson's OTTAVA Robotic Surgery System Targets Long-Term Growth

MarketBeat · 3 Aug 2026positive

Johnson & Johnson outlined commercialization plans for its OTTAVA robotic surgical system after receiving FDA De Novo authorization, positioning the table-integrated platform as a long-term growth initiative.

Why it matters — JNJ watchers would care because the OTTAVA system represents a significant step into the surgical robotics market, a key area for the company's future growth.

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Bloomberg Markets and Finance · 2 Aug 2026neutral

Johnson & Johnson has won FDA approval for its new surgical robot, Ottava, after years of development and an investment of hundreds of millions of dollars. The approval raises the question of whether Ottava can challenge competitors that entered the surgical robotics market years earlier.

Why it matters — A J&J watcher would care because FDA approval for Ottava marks a milestone in the company's surgical robotics business and tests whether J&J can compete in a market where rivals already have a head start.

FAQ

Frequently asked questions about JNJ stock

What is the JNJ stock price forecast for 2026-2027?

The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $274, with estimates ranging from $190 to $305. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is JNJ stock a buy right now?

Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 94 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank JNJ?

As at 1 Aug 2026, Johnson & Johnson ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will JNJ stock go up?

No one can know that. What the data says: the median 12-month target from 23 analysts implies +7.7% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 94 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the JNJ stock forecast for 2030?

No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $305 over the next 12 months.

How has JNJ stock performed over the past year?

Johnson & Johnson returned +55.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Johnson & Johnson do?

Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, which focuses on pharmaceuticals including treatments for immunology, oncology, infectious diseases, neuroscience, cardiovascular and metabolic disorders, and pulmonary hypertension; and MedTech, which provides advanced surgical equipment, devices for orthopaedics, vision care, and solutions for robotics, navigation, and digital technologies.

What is the latest news on JNJ?

The most recent item we track (Seeking Alpha, 3 Aug 2026): "Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript". The item is a transcript of Johnson & Johnson discussing the FDA authorization and market introduction of its OTTAVA robotic surgical system, as published on Seeking Alpha. It covers the company's remarks on the system's regulatory status and launch plans.

Company

About Johnson & Johnson.

Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, which focuses on pharmaceuticals including treatments for immunology, oncology, infectious diseases, neuroscience, cardiovascular and metabolic disorders, and pulmonary hypertension; and MedTech, which provides advanced surgical equipment, devices for orthopaedics, vision care, and solutions for robotics, navigation, and digital technologies. The company delivers innovative medicines and medical technologies that address unmet patient needs across diverse therapeutic areas, supporting healthcare professionals and consumers globally. Johnson & Johnson plays a pivotal role in the healthcare sector by advancing medical innovation and improving health outcomes through its broad portfolio of branded products and services. Founded in 1887 and headquartered in New Brunswick, New Jersey, it remains a cornerstone of the global health technology and pharmaceuticals industry.

CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com